PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION- WHO ARE THE “UNTREATED PATIENTS” IN HOSPITALS WITH CATH LAB?

Author(s)

Bashar Hamad, Phd, Market Analyst Acute Cardiovascular, Paola Isabelle Nasuti, MPharm, (Hon), Product Manager Acute Cardiovascular and Stroke, Jonathan Belilty, MPharm, Market Analyst Acute Cardiovascular and StrokeIMS Health, London, United Kingdom

OBJECTIVES: STEMI patients (pts) presenting <12h since onset of symptoms should receive reperfusion therapy, which results in important mortality reduction. However, critical presentation timing is not the only factor that influences treatment choice for STEMI pts. In this study we assess the scale at which clinical guidelines are followed in the treatment of STEMI patients presenting within the timeframe of reperfusion therapy.Methods: This was a retrospective patient diary study using the IMS Health Acute Cardiovascular Analyzer.  The study was conducted in 264 hospitals with Cath-Lab facilities in France, Germany, Italy, Spain and UK. They treated a total of 2553 patients diagnosed with STEMI, during the period of August 2006 and April 2007, with a mean of 10 patients per hospital. Hospitals were selected to be representative by geographic regions, size and facilities in each country. We analysed the data to determine factors associated with patients not receiving reperfusion therapy.Results: We found 2333 (91%) pts were admitted within 12 hours of onset of symptoms, where 49% had primary PCI, 16% received thrombolytics, 15% received thrombolytics and PCI, 8% had PCI outside the 12 hours reperfusion window, 9% didn’t receive PCI neither thrombolytics, 2 % had CABG: We report data from 393 patients who didn’t receive reperfusion therapy and accounts for patients not receiving primary PCI or thrombolytics: 66% had dyslipidaemia, 63% hypertension, 37% CHF, 30% diabetes, 19% age >80, 12% stable angina and 11% with PAD.  Also, it was noted that 40% of these patients experienced delay in-hospital diagnosis, and thus haven’t received reperfusion therapy within the 12 hours window, 10% were contraindicated to thrombolytics, and 39% were scheduled to receive revascularisation. In-hospital mortality accounted for 14% of the total untreated population. Conclusion: This study concludes that 17% of STEMI patients admitted to Cath Lab hospitals within 12 hours of onset of symptoms in Europe don’t receive reperfusion therapy even when catheralization facilities are available.

Conference/Value in Health Info

2008-11, ISPOR Europe 2008, Athens, Greece

Value in Health, Vol. 11, No. 6 (November 2008)

Code

PCV113

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Hospital and Clinical Practices

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×